09/02/2026
This week, we’re highlighting BELSOMRA® (suvorexant), developed by Merck for adults with insomnia who have difficulty falling asleep and/or staying asleep.
BELSOMRA introduced a different approach to insomnia treatment by targeting the orexin system, which plays an important role in promoting wakefulness. Rather than broadly inducing sleep, the therapy is designed to reduce wake signaling by blocking orexin receptors.
Since its launch, it brought a distinctive mechanism into a familiar but highly competitive category, creating a clear strategic story around the biology of wakefulness and the challenge of helping patients transition from being awake to asleep.
Learn more: https://www.belsomra.com/